BBIO · BridgeBio Pharma
137 filings
BBIO SEC Filings
BridgeBio Pharma - 137 total filings
BBIO filed 7 annual reports (10-K), 23 quarterly reports (10-Q) and 107 current reports (8-K) between 2019 and 2026.
- 8-K · Jul 3, 2019
- 10-Q · Aug 14, 2019
- 8-K · Sep 12, 2019
- 8-K · Oct 11, 2019
- 10-Q · Nov 8, 2019
- 8-K · Nov 19, 2019
- 8-K · Dec 17, 2019
- 8-K · Dec 26, 2019
- 8-K · Jan 7, 2020
- 8-K · Feb 19, 2020
- 8-K · Mar 2, 2020
- 10-K · Mar 3, 2020
- 8-K · Mar 4, 2020
- 8-K · Mar 6, 2020
- 8-K · Mar 10, 2020
- 8-K · Mar 24, 2020
- 8-K · Apr 29, 2020
- 8-K · May 13, 2020
- 10-Q · May 14, 2020
- 8-K · Jun 8, 2020
- 8-K · Jun 24, 2020
- 8-K · Aug 11, 2020
- 10-Q · Aug 11, 2020
- 8-K · Sep 29, 2020
- 8-K · Oct 5, 2020
- 8-K · Oct 6, 2020
- 8-K · Oct 23, 2020
- 10-Q · Nov 5, 2020
- 8-K · Nov 5, 2020
- 8-K · Nov 6, 2020
- 8-K · Jan 4, 2021
- 8-K · Jan 12, 2021
- 8-K · Jan 20, 2021
- 8-K · Jan 26, 2021
- 8-K · Jan 26, 2021
- 8-K · Jan 29, 2021
- 8-K · Feb 17, 2021
- 10-K · Feb 25, 2021
- 8-K · Feb 26, 2021
- 8-K · Mar 31, 2021
- 8-K · Apr 15, 2021
- 10-Q · May 6, 2021
- 8-K · May 11, 2021
- 8-K · May 14, 2021
- 8-K · Jun 1, 2021
- 8-K · Jun 22, 2021
- 10-Q · Aug 5, 2021
- 8-K · Aug 13, 2021
- 8-K · Aug 23, 2021
- 8-K · Oct 26, 2021
- 8-K · Nov 4, 2021
- 10-Q · Nov 4, 2021
- 8-K · Nov 18, 2021
- 8-K · Dec 16, 2021
- 8-K · Dec 27, 2021
- 8-K · Feb 24, 2022
- 10-K · Feb 25, 2022
- 10-Q · May 5, 2022
- 8-K · May 10, 2022
- 8-K · May 13, 2022
- 8-K · May 18, 2022
- 8-K · Jun 24, 2022
- 8-K · Jul 26, 2022
- 10-Q · Aug 4, 2022
- 8-K · Aug 4, 2022
- 8-K · Sep 23, 2022
- 10-Q · Nov 3, 2022
- 8-K · Nov 3, 2022
- 8-K · Dec 6, 2022
- 8-K · Feb 23, 2023
- 10-K · Feb 23, 2023
- 8-K · Mar 6, 2023
- 8-K · Mar 9, 2023
- 8-K · May 4, 2023
- 10-Q · May 4, 2023
- 8-K · May 4, 2023
- 8-K · Jun 22, 2023
- 8-K · Jul 17, 2023
- 8-K · Aug 3, 2023
- 10-Q · Aug 3, 2023
- 8-K · Sep 25, 2023
- 10-Q · Nov 2, 2023
- 8-K · Nov 2, 2023
- 8-K · Jan 8, 2024
- 8-K · Jan 18, 2024
- 10-K · Feb 22, 2024
- 8-K · Feb 22, 2024
- 8-K · Mar 4, 2024
- 8-K · Mar 6, 2024
- 8-K · May 2, 2024
- 10-Q · May 2, 2024
- 8-K · Jun 6, 2024
- 8-K · Jun 24, 2024
- 8-K · Jul 23, 2024
- 10-Q · Aug 1, 2024
- 8-K · Aug 1, 2024
- 8-K · Aug 21, 2024
- 8-K · Sep 11, 2024
- 10-Q · Nov 12, 2024
- 8-K · Nov 12, 2024
- 8-K · Nov 25, 2024
- 8-K · Jan 13, 2025
- 10-K · Feb 20, 2025
- 8-K · Feb 20, 2025
- 8-K · Feb 28, 2025
- 8-K · Mar 17, 2025
- 8-K · Apr 29, 2025
- 10-Q · Apr 29, 2025
- 8-K · Jun 23, 2025
- 8-K · Jul 2, 2025
- 10-Q · Aug 5, 2025
- 8-K · Aug 5, 2025
- 8-K · Oct 27, 2025
- 8-K · Oct 29, 2025
- 10-Q · Oct 29, 2025
- 8-K · Oct 29, 2025
- 8-K · Jan 12, 2026
- 8-K · Jan 21, 2026
- 8-K · Feb 12, 2026
- 8-K · Feb 24, 2026
- 10-K · Feb 24, 2026
- 8-K · Mar 30, 2026
- 10-Q · May 7, 2026
- 8-K · May 7, 2026
- 8-K · May 8, 2026
- 8-K · May 13, 2026
- 8-K · May 27, 2026
- 8-K · Jun 26, 2026
- 8-K · Jul 2, 2026
- 8-K · Jul 22, 2026
- 8-K · Aug 10, 2026
- 10-Q · Aug 10, 2026
- 8-K · Aug 17, 2026
- 8-K · Aug 31, 2026
- 8-K · Oct 13, 2026
- 8-K · Oct 29, 2026
- 10-Q · Oct 29, 2026
BridgeBio Pharma 8-K Report, Financial Results (Oct 29, 2026)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) reported third quarter 2026 results on October 29, 2026, with total revenues, net of $353.2 million, compared to $120.7 million in the third quarter of 2025. The increase was driven primarily by U.S. Attruby net product revenue of $253.2 million and a $75.0 million sales milestone from Bayer under the Bayer License Agreement recognized in the quarter. The company reported a loss from operations of $11.6 million and a net loss attributable to common stockholders of $83.0 million, or $0.42 per share, compared to $182.7 million, or $0.95 per share, a year earlier. Cash, cash equivalents and marketable securities were $1.5 billion as of September 30, 2026, up from $587.5 million at December 31, 2025, which the company says will fund its three potential launches and expansion indications. The company highlighted three PDUFA dates within roughly seven months: BBP-418 for LGMD2I/R9 on November 27, 2026, oral infigratinib for achondroplasia on February 4, 2027, and encaleret for ADH1 on May 8, 2027, each with Priority Review. Encaleret also began Phase 3 RECLAIM-HP in chronic hypoparathyroidism, with topline data expected in early 2028. Total operating costs and expenses rose to $364.8 million, driven by higher SG&A spending on commercialization and pre-commercial launch activities, and by higher R&D spending. The company also reported real-world evidence for acoramidis versus tafamidis, including an 18% lower risk of a composite outcome in an Epic COSMOS analysis of 2,684 patients, and new cardiac MRI data from ATTRibute-CM and its extension. Operating expenses and other expense, net of $47.6 million weighed on results, and the filing notes preferred stock dividends and accretion of $26.3 million in the quarter.
BridgeBio Pharma Quarterly Report for Q3 Ended Sep 30, 2026
BridgeBio Pharma reported a sharply higher top line for the third quarter of 2026 while losses narrowed. Total revenues, net were $353.2 million for the three months ended September 30, 2026, compared with $120.7 million a year earlier, driven by net product revenue of $253.3 million for Attruby and a $75.0 million sales milestone under the Bayer License Agreement. Net loss was $60.5 million for the quarter versus $184.9 million a year earlier. Net loss attributable to common stockholders was $83.0 million after $26.3 million of preferred stock dividends and accretion, which reflect the Series A preferred stock issued July 1, 2026. For the nine months, total revenues were $791.4 million and net loss was $382.9 million, against $538.3 million in the prior-year period. The balance sheet and financing activity changed materially. Cash, cash equivalents and marketable securities were $1.54 billion at September 30, 2026, up from $587.5 million at December 31, 2025. Financing included $933.9 million from the Series A preferred stock, $632.5 million of 0.75% convertible notes due 2033, and $933.9 million in preferred proceeds. The company repurchased common stock and holds a $500.0 million share repurchase program, with $325.0 million remaining at quarter end per the filing's table. Total stockholders' deficit narrowed to $1.65 billion from $2.08 billion. Total debt includes $2.5 billion of convertible notes and $920.1 million of deferred royalty obligations. The 2027 Notes, $550.0 million principal, are classified as current and mature March 15, 2027. The filing names three NDAs with FDA Priority Review: oral BBP-418 for LGMD2I/R9 with a PDUFA date of November 27, 2026; encaleret for ADH1 with a PDUFA date of May 8, 2027; and low-dose infigratinib for achondroplasia with a PDUFA date of February 4, 2027. Management states that cash and marketable securities together with product collections should fund operations for at least the next 12 months. Operating cash outflow was $312.6 million for the nine months.
BridgeBio Pharma 8-K Report, Corporate Update (Oct 13, 2026)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) filed this Form 8-K on October 13, 2026, under Item 8.01 (Other Events) to furnish a press release dated October 6, 2026. The press release announces that the FDA accepted for filing the company's New Drug Application (NDA) for oral infigratinib for the treatment of children with achondroplasia, granted Priority Review, and assigned a PDUFA target action date of February 4, 2027. BridgeBio says it is prepared to launch oral infigratinib in the U.S. upon approval. The company cites PROPEL 3, its global Phase 3 pivotal study, which met its primary endpoint of change from baseline in annualized height velocity at Week 52 (mean treatment difference of +2.10 cm/year; p<0.0001) and its key secondary endpoint of change in height Z-score (p<0.0001). The release also reports statistically significant improvements in arm span (z-score +0.37 SD, p<0.0001) and body proportionality (mean difference of -0.05 in ages 3-8, p<0.05, described as a pre-specified exploratory analysis), along with favorable exploratory trends in sleep apnea and otitis media events. The company states that oral infigratinib was well tolerated, with no discontinuations or serious adverse events related to study drug. The data were published in The New England Journal of Medicine and presented at the International Congress of Children's Bone Health 2026. The filing also notes that oral infigratinib holds Breakthrough Therapy Designation, Orphan Drug, Fast Track and Rare Pediatric Disease Designations from the FDA, and Orphan Drug Designation from the EMA. BridgeBio intends to submit a Marketing Authorization Application to the European Medicines Agency in the fourth quarter of 2026. The forward-looking statements caution that trial results, regulatory timing, and approval are uncertain.
BridgeBio Pharma 8-K Report, Corporate Update (Aug 31, 2026)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) reported in an Item 8.01 Other Event filing dated August 31, 2026 that it has entered into a voluntary agreement with the U.S. government to expand access to its medicines and lower costs for American patients. As part of the agreement, BridgeBio will expand state Medicaid access to its currently marketed medicine, Attruby (acoramidis), via the GENEROUS Model. The company states that it does not expect to be subject to future pricing mandates, and that the specific terms of the agreement remain confidential. The company also expects that its pricing commitment for future medicines under the agreement will exclude medicines approved exclusively for orphan indications. The filing states that BridgeBio will continue to offer Attruby via Medicare Part D without any future pricing mandates, and that the agreement has no impact on its ForgingBridges copay assistance program, which can reduce out-of-pocket costs to as little as $0 per month for qualifying patients. The filing's forward-looking statements flag risks, including that the agreement may be implemented or interpreted differently than expected, that additional pricing mandates could be imposed, and that government pricing or reimbursement policies could change. The company's pipeline referenced in the press release includes BBP-418 (PDUFA date with Priority Review: November 27, 2026), encaleret (PDUFA date with Priority Review: May 7, 2027), and infigratinib for achondroplasia, which is under FDA review.
BridgeBio Pharma 8-K Report, Material Agreement (Aug 17, 2026)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) filed this Form 8-K to disclose a secondary offering of 5,000,000 shares of its common stock by the selling stockholder KKR Genetic Disorder L.P. The Company entered into an Underwriting Agreement dated August 13, 2026 with William Blair & Company, L.L.C., Goldman Sachs & Co. LLC and KKR Capital Markets LLC, as representatives of the underwriters, with the shares priced at $78.00 per share. The Company will not receive any proceeds from the sale of the shares, which is expected to complete on August 17, 2026. The offering was made under the Company's effective automatic shelf registration statement on Form S-3ASR (File No. 333-297701), with a prospectus dated July 24, 2026 and a prospectus supplement dated August 13, 2026, filed August 14, 2026. The Company issued a launch press release on August 13, 2026 and a pricing press release on August 14, 2026, which describes the offering as oversubscribed and as diversifying the institutional shareholder base. For investors, the transaction is a secondary sale by an existing holder and does not involve new capital raised by the Company. The filing includes the Underwriting Agreement, a legal opinion from Goodwin Procter LLP, and the related press releases as exhibits.
BridgeBio Pharma Quarterly Report for Q2 Ended Jun 30, 2026
BridgeBio Pharma, Inc. reported a quarter ended June 30, 2026 with total revenues, net of $243.7 million for the three months, up from $110.6 million a year earlier, driven by net product revenue of $222.4 million (versus $71.5 million), which reflects Attruby. License and services revenue declined to $5.8 million from $37.4 million, as the prior-year period included a $30.0 million regulatory milestone. Net loss attributable to common stockholders was $152.2 million, or $(0.78) per share, compared with $181.9 million, or $(0.95) per share, in the prior-year quarter. For the six months, total revenues were $438.2 million and net loss attributable to common stockholders was $316.3 million. Operating expenses rose, with research and development at $149.4 million and selling, general and administrative expenses at $186.3 million for the quarter. Cash, cash equivalents and marketable securities totaled $720.2 million at June 30, 2026, against total debt of approximately $2.5 billion in convertible notes plus $908.7 million of deferred royalty obligations. The company issued $632.5 million of 0.75% convertible notes due 2033 in January 2026, and stockholders' deficit stood at $(2.5) billion. The company states that cash and marketable securities together with product collections should fund operations for at least the next 12 months. Subsequent to quarter-end, on July 1, 2026, BridgeBio sold 933,900 shares of Series A Cumulative Convertible Participating Preferred Stock for $933.9 million in gross proceeds to Sixth Street-affiliated and KKR-affiliated purchasers, at a 7.00% initial dividend rate and a $137.79 initial conversion price. The company also disclosed a $500.0 million at-the-market program and a $500.0 million share repurchase program approved in May 2026, under which it repurchased 1,904,001 shares for approximately $127.5 million through June 30, 2026. Regulatory milestones include a PDUFA target action date of November 27, 2026 for BBP-418 and May 8, 2027 for encaleret.
BridgeBio Pharma 8-K Report, Financial Results (Aug 10, 2026)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) reported second quarter 2026 results on August 10, 2026, furnished as Exhibit 99.1 to this Form 8-K under Item 2.02. Total revenues, net were $243.7 million for the quarter, comprised of $222.4 million of U.S. Attruby net product revenue, $15.4 million of royalty revenue, and $5.8 million of license and services revenue, compared with $110.6 million in the same period of 2025. Total operating costs and expenses rose to $350.8 million from $244.8 million, and the net loss attributable to common stockholders of BridgeBio was $152.2 million, or $0.78 per share, versus $181.9 million, or $0.95 per share, a year earlier. The company reported $720.2 million in cash, cash equivalents, and marketable securities as of June 30, 2026, excluding a $1 billion preferred equity financing led by Sixth Street that closed on July 1, 2026. The company states that all three planned NDAs have now been submitted to the FDA: BBP-418 for LGMD2I/R9 and encaleret for ADH1 were each accepted with Priority Review, with PDUFA target dates of November 27, 2026 and May 8, 2027, respectively, and no advisory committee planned for either. Oral infigratinib for achondroplasia has been submitted, with a U.S. launch expected in mid-2027. Management highlighted new kidney-related post-hoc analyses for Attruby published in Circulation: Heart Failure, along with real-world evidence comparing acoramidis with tafamidis. The company also noted a Commercial Day in New York City on October 8, 2026, and ongoing pipeline expansion efforts including RECLAIM-HP, CALIBRATE-PEDS, and a hypochondroplasia Phase 2 update expected in the second half of 2026.
BridgeBio Pharma 8-K Report, Corporate Update (Jul 22, 2026)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced in a Form 8-K dated July 22, 2026 that the U.S. FDA has accepted for filing its New Drug Application (NDA) for encaleret for the treatment of autosomal dominant hypocalcemia type 1 (ADH1). The FDA assigned a PDUFA target action date of May 8, 2027, and the company says it is prepared to launch encaleret upon approval, which it describes as a potential blockbuster opportunity. The FDA also indicated it is not currently planning to hold an advisory committee meeting on the application. The company states that the Phase 3 CALIBRATE trial in ADH1 achieved all pre-specified primary and key secondary efficacy endpoints, with additional results presented at the European Congress of Endocrinology 2026 and the Endocrine Society 2026 annual meeting. BridgeBio says encaleret normalized key markers of calcium-sensing receptor-driven disease biology without the need for calcium and vitamin D supplements, and reports a favorable safety and tolerability profile. The company also cites claims data showing more than 2,100 U.S. individuals diagnosed with autosomal dominant hypocalcemia since October 2023 as of April 2026. BridgeBio also stated it is enrolling CALIBRATE-PEDS, a registrational Phase 2/3 study in pediatric ADH1, intends to submit a Marketing Authorization Application to the European Medicines Agency in the second half of 2026, and plans to initiate the RECLAIM-HP Phase 3 study in chronic hypoparathyroidism later this summer. The filing itself is an Item 8.01 disclosure that incorporates the press release by reference as Exhibit 99.1.
BridgeBio Pharma 8-K Report, Material Agreement (Jul 2, 2026)
On July 1, 2026, BridgeBio Pharma, Inc. (Nasdaq: BBIO) entered into an Investment Agreement with purchasers including Chinotto Investments, LLC (a Sixth Street entity) and HCRx Investments HoldCo, L.P. (an affiliate of KKR's HealthCare Royalty), issuing 933,900 shares of Series A Cumulative Convertible Participating Preferred Stock at $1,000 per share for an aggregate purchase price of $933.9 million. Sixth Street purchased 800,000 shares ($800.0 million) and HCRx purchased 133,900 shares ($133.9 million). Sixth Street or its affiliates also have a right, subject to Board approval, to provide up to an additional $66.1 million on substantially identical terms, bringing the total potential investment to $1.0 billion. The filing notes that HCRx is affiliated with KKR, a holder of more than 5% of the Company's Common Stock, and that director Ali Satvat is a partner there. The Preferred Stock ranks senior to common stock on dividends and liquidation. It accrues dividends at 7.00% per annum, payable quarterly in cash or compounded into the Accumulated Amount at the Company's option, with step-ups including 500 basis points on the seventh anniversary of the July 1, 2026 issuance date, and a cap of 17.00%. Initial conversion price is $137.79 per share, rising to $153.10 on the fifth anniversary. The initial purchased shares are convertible into 6,777,705 shares of Common Stock. Holders have no redemption right at their option; the Company may redeem from the third anniversary onward at a formula-based price, and conversion is subject to a 19.9% beneficial ownership limitation until stockholder approval is obtained. The Company has agreed to seek that approval at its 2027 annual meeting or a special meeting no later than June 30, 2027, if required by Nasdaq rules. The issuance dilutes common holders' economic and voting rights, as the Preferred Stock votes with common on an as-converted basis and carries separate class consent rights over certain actions, including incurring certain indebtedness and making certain restricted payments. The Company's press release characterizes the transaction as a $1 billion financing to support launches of Attruby and three additional U.S. product candidates (BBP-418, encaleret and infigratinib) over the next 12 months.
BridgeBio Pharma 8-K Report, Executive Changes (Jun 26, 2026)
BridgeBio Pharma, Inc. filed this Form 8-K on June 26, 2026 to report the results of its 2026 Annual Meeting of Stockholders, held June 22, 2026. Of the 195,806,242 shares entitled to vote, 175,706,357 were present in person or by proxy. Dr. Randal W. Scott resigned from the Board of Directors effective June 22, 2026, upon completing his term as a Class I director. The filing states that his resignation was not due to any disagreement with the Company on its operations, policies or practices. Stockholders elected three Class I directors to serve until the 2029 Annual Meeting: James C. Momtazee, Frank P. McCormick, Ph.D., and Hannah A. Valantine, M.D. Stockholders also approved, on an advisory basis, the compensation of the named executive officers, with 152,949,577 votes for, 6,938,080 against and 1,219,213 abstentions. They ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 175,420,234 votes for and 203,310 against. Stockholders also approved an amendment and restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan, which increases the shares reserved for issuance by 2,000,000. That proposal received 132,402,786 votes for and 27,350,537 against. On the frequency of future say-on-pay votes, stockholders favored an annual vote, with 154,371,970 votes for every 1 Year, compared with 5,199,700 for 2 Years and 1,467,447 for 3 Years. Following the Board's recommendation and consistent with that preference, the Company plans to hold these advisory votes every year. The amended and restated plan is filed as Exhibit 10.1.
BridgeBio Pharma 8-K Report, Corporate Update (May 27, 2026)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) filed a Form 8-K on May 27, 2026 under Item 8.01 (Other Events) to announce that the U.S. Food and Drug Administration accepted for filing its New Drug Application (NDA) for oral BBP-418 for the treatment of limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), with Priority Review. The FDA assigned a PDUFA target action date of November 27, 2026, and the company is poised to launch the drug upon approval. The FDA also indicated it is not currently planning to hold an advisory committee meeting to discuss the application. According to the attached press release (Exhibit 99.1), BBP-418 met all primary and secondary endpoints at the pre-specified 12-month interim analysis of the Phase 3 FORTIFY trial, with treated individuals improving while placebo recipients declined on every key measure. The company states that, if approved, BBP-418 would be the first and only therapy for LGMD2I/R9 and the first approved treatment for any form of LGMD. BBP-418 has already received Orphan Drug, Fast Track, and Rare Pediatric Disease Designations from the FDA, and Orphan Drug Designation from the European Medicines Agency; BridgeBio may qualify for a Priority Review Voucher if approved. The filing is primarily a regulatory milestone disclosure and contains no financial figures. The filing does not provide commercial projections, revenue estimates, or financial guidance. The company also states it is engaging regulatory agencies to identify an expedited path to approval in Europe and intends to initiate clinical studies in younger patients and in related LGMD subtypes.
BridgeBio Pharma 8-K Report, Corporate Update (May 13, 2026)
BridgeBio Pharma, Inc. filed this Form 8-K under Item 8.01 (Other Events) to report that on May 12, 2026 it issued a press release announcing the submission of its New Drug Application (NDA) to the FDA for encaleret as a potential treatment for autosomal dominant hypocalcemia type 1 (ADH1). The press release is attached as Exhibit 99.1 and incorporated by reference. No financial statements are included in this filing. According to the press release, the Phase 3 CALIBRATE trial met all pre-specified primary and key secondary efficacy endpoints. 76% of participants randomized to encaleret achieved both target serum and urine calcium levels at Week 24, compared with 4.4% of the same individuals while on standard of care, and with 19% of participants who remained on standard of care at Week 24 (p<0.0001). The company reports that encaleret restored endogenous parathyroid hormone in 91.1% of participants on encaleret versus 0% on standard of care at Week 24, and that there were no discontinuations in the encaleret arm. BridgeBio states that encaleret may be eligible for priority review and anticipates a U.S. launch in early 2027. If approved, it could be the first therapy specifically indicated for ADH1. The company also plans to submit a Marketing Authorization Application to the European Medicines Agency in the second half of 2026, begin the RECLAIM-HP Phase 3 study in chronic hypoparathyroidism in Summer 2026, and continues to enroll the CALIBRATE-PEDS study in pediatric ADH1.
BridgeBio Pharma 8-K Report, Material Agreement (May 8, 2026)
On May 7, 2026, BridgeBio Pharma, Inc. entered into an Equity Distribution Agreement with Goldman Sachs & Co. LLC and Leerink Partners LLC establishing an at-the-market offering program under which the Company may sell shares of its common stock, par value $0.001 per share, having an aggregate offering price of up to $500,000,000. The Company is not obligated to make any sales, and either the Company or the Sales Agents may suspend or terminate the offering upon notice. The Sales Agents will act on a best efforts basis, and the Company will pay them a commission of up to 3.0% of gross proceeds from any shares sold. The offering is made under a registration statement on Form S-3ASR (File No. 333-295678) that the Company filed on May 7, 2026 under Rule 415 of the Securities Act. The filing also discloses that, in connection with the new agreement, the Company agreed with Goldman Sachs and Leerink Partners (formerly known as SVB Securities LLC) to terminate the Equity Distribution Agreement dated May 4, 2023, effective May 7, 2026. The filing is a capital-markets administrative update rather than an operational or clinical disclosure. It establishes financing flexibility of up to $500 million for investors to monitor, but it does not state how much, if any, stock has been sold or the intended use of proceeds.
BridgeBio Pharma Quarterly Report for Q1 Ended Mar 31, 2026
BridgeBio Pharma, Inc. (BridgeBio) reported a net loss of $166.6 million for the three months ended March 31, 2026, compared with $169.6 million in the same period of 2025. Total revenues, net were $194.5 million, up from $116.6 million, driven by net product revenue of $180.6 million (versus $36.7 million), while license and services revenue fell to $4.4 million from $79.7 million, which the filing attributes mainly to $75.0 million of milestone revenue recognized in 2025 following Beyonttra's EU approval. Royalty revenue rose to $9.5 million. Operating expenses increased, with selling, general and administrative expenses at $163.9 million (up from $106.4 million) and research and development at $126.6 million (up from $111.4 million). Net cash used in operating activities was $197.3 million. Balance sheet activity was dominated by financing. In January 2026 the company issued $632.5 million of 0.75% convertible senior notes due 2033 and used $82.5 million of proceeds to repurchase 1,081,825 shares of common stock. As of March 31, 2026, cash, cash equivalents and marketable securities totaled $940.2 million, and the company reported stockholders' deficit of $2.27 billion, with the 2027 Notes classified as current. Management states that existing cash and marketable securities and Attruby revenue are expected to fund operations for at least the next 12 months. On May 6, 2026, the Board approved a stock repurchase program of up to $500.0 million. The filing also notes that the company submitted a New Drug Application to the FDA for oral BBP-418 for LGMD2I/R9 on March 30, 2026, and that the 2027 and 2031 Notes became convertible for a limited period from April 1, 2026 through June 30, 2026 after a conversion condition was met.
BridgeBio Pharma 8-K Report, Financial Results (May 7, 2026)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) reported first-quarter 2026 results on May 7, 2026, with total revenues, net of $194.5 million, up from $116.6 million a year earlier. The increase was driven mainly by a $143.9 million rise in net product revenue from Attruby, to $180.6 million, and a $9.3 million rise in royalty revenue. Total operating costs and expenses rose to $300.5 million from $221.0 million, led by higher SG&A spending tied to Attruby commercialization and pre-commercial activities for its Phase 3 candidates. The net loss attributable to common stockholders of BridgeBio was $164.0 million, or $0.84 per share, compared with $167.4 million, or $0.88 per share, in the prior-year quarter. Cash, cash equivalents and marketable securities were $940.2 million at March 31, 2026, up from $587.5 million at December 31, 2025. The Board approved a share repurchase program of up to $500 million of common stock on May 6, 2026. The filing states that repurchases may be made in the open market or in privately negotiated transactions, and that the program does not obligate the company to repurchase any amount and may be suspended or discontinued at any time. The CEO's quoted remarks say the company is fully financed and trading at a deep discount to intrinsic value, which is why it considers buybacks prudent. Pipeline news includes the first of three planned NDAs submitted to the FDA for BBP-418 in LGMD2I/R9, with encaleret for ADH1 NDA submission planned for the first half of 2026 and oral infigratinib for achondroplasia planned for the third quarter of 2026. The filing also reports Brazilian approval of acoramidis (BEYONTTRA) for ATTR-CM on May 4, 2026.
BridgeBio Pharma 8-K Report, Corporate Update (Mar 30, 2026)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) filed a Current Report on Form 8-K on March 30, 2026, furnishing a press release announcing the submission of its New Drug Application (NDA) to the FDA for oral BBP-418 for the treatment of individuals living with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The company states that FORTIFY, the Phase 3 trial of BBP-418, met all pre-specified primary and secondary endpoints of its 12-month interim analysis, with additional positive results on rapid and consistent treatment effect and favorable safety profile presented at the 2026 MDA Clinical and Scientific Conference. BridgeBio anticipates approval and a U.S. launch in late 2026/early 2027, based on ongoing discussions with the FDA. If approved, BBP-418 would be the first and only approved therapy for individuals with LGMD2I/R9 and may represent the first approved treatment for any form of LGMD. The company is also engaging regulatory agencies to identify an expedited path to approval in Europe, where BBP-418 holds Orphan Drug Designation from the EMA. The NDA may be eligible for Priority Review given Fast Track designation, and if approved, BridgeBio may qualify for a Priority Review Voucher under the Rare Pediatric Disease designation. The company also intends to initiate clinical studies in LGMD2I/R9 for individuals under 12 years of age and in LGMD2M/2U in the near future.
BridgeBio Pharma Annual Report, Year Ended Dec 31, 2025
BridgeBio Pharma, Inc. (BBIO) reports that it is a commercial-stage, multi-product biopharmaceutical company organized around a portfolio operating model. Its largest product, Attruby (acoramidis) for ATTR-CM, generated $362.4 million in U.S. net product revenue in 2025, and total revenues, net were $502.1 million for 2025 compared with $221.9 million in 2024. The company still reported a net loss of $732.9 million for 2025 (versus $543.3 million in 2024), an accumulated deficit of $3.8 billion, and a working capital deficit position reflected in total stockholders' deficit of $2.08 billion at year-end. Cash, cash equivalents and marketable securities were $587.5 million as of December 31, 2025, and management states these resources plus Attruby revenue should fund operations for at least the next 12 months. The filing highlights substantial debt and royalty obligations: total consolidated indebtedness of $1.9 billion in convertible notes and deferred royalty obligations of $866.3 million. In January 2026 BridgeBio issued $632.5 million of 0.75% convertible senior notes due 2033. Pipeline catalysts include positive Phase 3 data for infigratinib in achondroplasia (PROPEL 3, February 2026), encaleret in ADH1 (CALIBRATE, October 2025) and BBP-418 in LGMD2I/R9 (FORTIFY interim analysis, October 2025), with NDA submissions planned for 2026 and an infigratinib MAA/NDA planned for the second half of 2026. Beyonttra (acoramidis) is commercialized ex-U.S. through partners Bayer (Europe) and Alexion (Japan). Investors should weigh the commercial ramp of Attruby and the late-stage pipeline against continued losses, heavy operating expenses (selling, general and administrative expenses rose to $531.2 million), reliance on third-party manufacturers, and the cost and dilution implications of its debt and royalty financings. Exposure to U.S. drug pricing reforms, including proposed GLOBE and GUARD models and most-favored-nation initiatives, is also flagged as a risk to future revenue.
BridgeBio Pharma 8-K Report, Financial Results (Feb 24, 2026)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) reported financial results for the fourth quarter and full year ended December 31, 2025 in a press release furnished as Exhibit 99.1 to this Form 8-K. Total revenues, net were $154.2 million for the fourth quarter and $502.1 million for the full year, led by U.S. Attruby net product revenue of $146.0 million in the quarter and $362.4 million for the year. Net loss attributable to common stockholders of BridgeBio was $192.9 million for the quarter and $724.9 million for the year, or $(1.00) and $(3.78) per share. Total operating costs and expenses for the full year were $1.0 billion, with selling, general and administrative expenses of $531.2 million reflecting commercial launch investments for Attruby. Cash, cash equivalents and marketable securities totaled $587.5 million as of December 31, 2025, down from $681.1 million a year earlier. The company stated that net cash used in operating activities was $445.9 million for 2025. In January 2026, BridgeBio completed issuance of $632.5 million aggregate principal amount of Convertible Senior Notes due 2033, which it describes as part of a strategy to lower interest expense, reduce dilution and extend debt maturity. Pipeline progress was the main focus of the update. The company reported positive Phase 3 results for BBP-418 (FORTIFY interim analysis), encaleret (CALIBRATE) and infigratinib (PROPEL 3), and plans NDA submissions for BBP-418 and encaleret in the first half of 2026 and for infigratinib in the second half of 2026. The company also noted that BBP-418, BBP-812 and infigratinib may be eligible for a Rare Pediatric Disease Priority Review Voucher upon approval.
BridgeBio Pharma 8-K Report, Corporate Update (Feb 12, 2026)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) reported positive topline results from PROPEL 3, its global Phase 3 pivotal study of oral infigratinib in children with achondroplasia. The one-year, 2:1 randomized, double-blinded, placebo-controlled study met its primary endpoint, change from baseline in annualized height velocity (AHV) at Week 52 (p<0.0001), with an LS mean treatment difference of +1.74 cm/year versus placebo (mean treatment difference of +2.10 cm/year). The absolute AHV in the infigratinib arm was 5.96 cm/year versus 4.22 cm/year on placebo. The company also met its key secondary endpoint, change from baseline in height Z-score at Week 52 (p<0.0001), with an LS mean treatment difference of +0.32 SD and an LS mean increase of +0.41 SD on the treatment arm. In a pre-specified exploratory analysis of children younger than 8 years old (more than 50% of participants), infigratinib showed a statistically significant improvement in body proportionality against placebo, with an LS mean treatment difference of -0.05 (p<0.05). In the overall population, the treatment difference was -0.02 versus placebo (p=0.1849). The company reported that infigratinib was well tolerated, with no discontinuations or serious adverse events related to study drug. Three cases (4%) of hyperphosphatemia were reported, all mild and transient, and none required dose reduction or discontinuation. BridgeBio intends to meet with regulators to discuss New Drug Application (NDA) and Marketing Authorization Application (MAA) submissions for achondroplasia in the second half of 2026. The company also plans to accelerate development of infigratinib in hypochondroplasia and is enrolling the observational run-in for its Phase 3 trial in that indication. Infigratinib holds FDA Breakthrough Therapy Designation for achondroplasia, which the company describes as the only therapeutic option in development for achondroplasia with that designation. The company also referenced Orphan Drug, Fast Track, and Rare Pediatric Disease designations.
BridgeBio Pharma 8-K Report, Material Agreement (Jan 21, 2026)
On January 21, 2026, BridgeBio Pharma, Inc. closed a private offering under Rule 144A of $632.5 million aggregate principal amount of 0.75% Convertible Senior Notes due 2033. The total includes $82.5 million from the Initial Purchasers' exercise in full of their option. Net proceeds are approximately $619.3 million after the Initial Purchasers' discount and estimated offering expenses. BridgeBio intends to use the proceeds to repurchase, settle conversion obligations in respect of, or repay at maturity a portion of its 2.50% Convertible Senior Notes due 2027, and for general corporate purposes. The filing states that no assurance can be given as to how much of the 2027 Notes will be repurchased or when. The Notes are senior unsecured obligations that pay interest semiannually on February 1 and August 1, beginning August 1, 2026. They are convertible into cash, shares, or a combination at BridgeBio's election, with an initial conversion rate of 9.0435 shares per $1,000 principal amount, equal to an initial conversion price of approximately $110.58 per share. BridgeBio may not redeem the Notes before February 6, 2030, and its redemption right is conditioned on the stock trading at or above 130% of the conversion price. The Notes rank equally with the 2027, 2029 and 2031 convertible notes, and are effectively junior to secured debt, including obligations under a Funding Agreement dated January 17, 2024, and structurally junior to subsidiary liabilities. Concurrently with the pricing, BridgeBio used approximately $82.5 million of cash on hand to repurchase 1,081,825 shares of common stock from certain purchasers of the Notes in privately negotiated transactions at $76.26 per share, the January 15, 2026 closing price on Nasdaq. The filing notes these repurchases could have affected the market prices of the common stock or the Notes. Shares issuable on conversion are initially capped at 8,293,972 at a maximum conversion rate of 13.1130 shares per $1,000 principal amount, subject to anti-dilution adjustments. The Notes and underlying shares are unregistered securities.
BridgeBio Pharma 8-K Report, Financial Results (Jan 12, 2026)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) furnished an 8-K on January 12, 2026 with preliminary, unaudited financial information for the quarter and fiscal year ended December 31, 2025. The Company estimates net product revenue of $146.0 million for the fourth quarter of 2025 and $362.4 million for the full year 2025, and approximately $587.5 million of cash, cash equivalents and marketable securities as of December 31, 2025. The filing states that the audit of the consolidated financial statements is ongoing and could change these figures. The filing also furnishes the press release and J.P. Morgan Healthcare Conference slides, which center on Attruby (acoramidis), the company's commercial product for ATTR-CM. The release reports 6,629 unique patient prescriptions written by 1,632 prescribers as of December 31, 2025, and the slides estimate Attruby's share of new-to-brand prescriptions (NBRx) at more than 25%. The company also announced a new monoclonal antibody depleter program for ATTR-CM, expected to enter the clinic in 2027–2028. Pipeline updates include positive interim results from the Phase 3 FORTIFY study of BBP-418 in LGMD2I/R9, with a stated 2.6-point benefit on the North Star Assessment for Limb-Girdle Type Muscular Dystrophies (NSAD) versus placebo at 12 months, and an FDA recommendation to orient the NDA toward traditional approval, with NDA submission planned for the first half of 2026. The company also reported encaleret's CALIBRATE Phase 3 results in ADH1, planned NDA submission in the first half of 2026, and the start of the RECLAIM-HP Phase 3 trial in chronic hypoparathyroidism in summer 2026. Topline results for the PROPEL 3 Phase 3 study of infigratinib in achondroplasia are expected by the end of the first quarter of 2026.
BridgeBio Pharma 8-K Report, Financial Results (Oct 29, 2025)
BridgeBio Pharma, Inc. reported third-quarter 2025 revenues, net of $120.7 million, consisting of $108.1 million in U.S. Attruby net product revenue, $4.3 million in royalty revenue, and $8.3 million in license and services revenue. Total revenues, net were $120.7 million for the quarter compared with $2.7 million in the prior-year period. The company reported a net loss attributable to common stockholders of $182.7 million, or $0.95 per share, for the quarter, compared with $162.0 million, or $0.86 per share, a year earlier. Total operating costs and expenses rose to $265.9 million from $194.5 million, driven mainly by a $68.8 million increase in selling, general and administrative expenses tied to the Attruby launch. Research and development expenses decreased, which the company attributed to the reprioritization of its R&D programs. As of October 25, 2025, 5,259 unique patient prescriptions had been written by 1,355 unique prescribers since Attruby's FDA approval in November 2024. Cash, cash equivalents and marketable securities totaled $645.9 million as of September 30, 2025, compared with $681.1 million as of December 31, 2024. The filing attributes the decrease primarily to $389.5 million of net cash used in operating activities over the nine months, the $459.0 million repayment of the previous term loan, and $48.3 million of common stock repurchases. These outflows were partly offset by $563.0 million in net proceeds from the 2031 Notes and $297.0 million in net proceeds from the royalty interest purchase and sale agreement with HealthCare Royalty, a related party, and Blue Owl Capital. On the pipeline, the company reported positive topline results from the FORTIFY Phase 3 study of BBP-418 for LGMD2I/R9 and the CALIBRATE Phase 3 study of encaleret for ADH1. It intends to file New Drug Applications for both programs with the FDA in the first half of 2026. The PROPEL 3 Phase 3 study of infigratinib in achondroplasia is expected to report topline results in early 2026.
BridgeBio Pharma Quarterly Report for Q3 Ended Sep 30, 2025
BridgeBio Pharma, Inc. reported its quarterly results for the period ended September 30, 2025 in this Form 10-Q. Total revenues, net were $120.7 million for the three months ended September 30, 2025, up from $2.7 million a year earlier, and $347.9 million for the nine months, up from $216.0 million. Net product revenue from Attruby was $108.1 million for the quarter and $216.4 million for the nine months. Net loss was $184.9 million for the quarter and $538.3 million for the nine months, compared with $164.3 million and $276.0 million in the prior-year periods. Net loss attributable to common stockholders was $532.1 million for the nine months, or $(2.79) per share. The balance sheet shows cash, cash equivalents and marketable securities of $645.9 million as of September 30, 2025, compared with $681.1 million at December 31, 2024. Total liabilities were $2.92 billion against total assets of $998.3 million, resulting in a total stockholders' deficit of $1.92 billion. The company issued $575.0 million of 1.75% convertible senior notes due 2031 in February 2025 and fully repaid its $450.0 million term loan, and it received $300.0 million from a royalty purchase agreement in June 2025. Deferred royalty obligations, net, stood at $836.1 million. Net cash used in operating activities was $389.5 million for the nine months. Management states that existing cash, cash equivalents and marketable securities are expected to fund operations for at least the next 12 months. The filing describes ongoing restructuring charges of $8.8 million for the quarter, a noncash interest expense of $36.4 million on deferred royalty obligations, and a share repurchase of 1,405,411 shares for $48.3 million in February 2025. Management notes that it expects to continue incurring operating and net losses for at least the next several years.
BridgeBio Pharma 8-K Report, Corporate Update (Oct 29, 2025)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) reported on October 29, 2025 positive topline results from CALIBRATE, its global Phase 3 study of encaleret, an investigational oral negative allosteric modulator of the calcium-sensing receptor, in patients with autosomal dominant hypocalcemia type 1 (ADH1). The study enrolled 70 adults and randomized 67 participants in a 2:1 ratio (encaleret vs. standard of care). The primary endpoint, achievement of both target serum and urine calcium ranges at Week 24, was met by 76% of encaleret-treated participants (34 of 45) versus 4% (2 of 45) on conventional therapy (p<0.0001). Key secondary endpoints were also met: 91% of participants on encaleret achieved intact PTH above the lower limit of the reference range at Week 24 versus 7% on conventional therapy at Week 4 (p<0.0001). The filing states that encaleret was well-tolerated, with no discontinuations related to study drug, and that safety findings were generally consistent with known ADH1 biology or related to the drug's mechanism of action. Among additional results, encaleret produced a mean increase in corrected calcium of 0.82 mg/dL from Week 4 to Week 24 (p<0.0001) and a mean reduction of 200 mg/day in 24-hour urine calcium over the same period (p<0.0001). 65 of 67 randomized participants (97%) elected to continue in the ongoing long-term extension. Management plans to submit a New Drug Application to the FDA in the first half of 2026 to support full approval, followed by a Marketing Authorization Application to the EMA. BridgeBio also plans to start a registrational trial in pediatric ADH1 in Q1 2026 and a Phase 3 study in adults with chronic hypoparathyroidism in 2026. Encaleret holds FDA Fast Track Designation and Orphan Drug Designation in the U.S., EU, and Japan. The company hosted an investor call on October 29, 2025 at 8:00 am ET to discuss the results.
BridgeBio Pharma 8-K Report, Corporate Update (Oct 27, 2025)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) furnished a Form 8-K on October 27, 2025 under Item 8.01 (Other Events) to report positive topline results from FORTIFY, its randomized, double-blind, placebo-controlled Phase 3 pivotal study of BBP-418, an investigational small molecule oral therapy for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The press release, attached as Exhibit 99.1, states that all primary and secondary interim analysis endpoints were achieved, with a well-tolerated safety profile consistent with prior studies and no new or unexpected safety findings. The primary interim analysis endpoint, glycosylated alpha-dystroglycan (αDG), increased by 1.8x from baseline at 3 months versus approximately no change in the placebo group (p<0.0001), and the increase was sustained at 12 months (p<0.0001). Average serum creatine kinase, a marker of muscle breakdown, fell 82% from baseline at 12 months (p<0.0001). Key clinical endpoints at 12 months also improved: 100-meter timed test velocity rose 0.14 m/s from baseline and 0.27 m/s versus placebo (p<0.0001), and FVC rose about 3% predicted from baseline with a difference of about 5% predicted versus placebo (p=0.0071). BridgeBio intends to engage the FDA later in 2025 and plans to submit a New Drug Application for BBP-418 in the first half of 2026. The company states that full interim analysis data are still being analyzed and that detailed results will be presented at a future medical meeting. The filing notes that BBP-418 holds Orphan Drug, Fast Track, and Rare Pediatric Disease Designations from the FDA and Orphan Drug Designation from the EMA, and that BridgeBio may qualify for a Priority Review Voucher if the drug is approved.
BridgeBio Pharma Quarterly Report for Q2 Ended Jun 30, 2025
BridgeBio Pharma, Inc. reported a net loss of $183.8 million for the three months ended June 30, 2025, compared with a net loss of $75.5 million in the same period of 2024, and a net loss of $353.4 million for the six months ended June 30, 2025 (versus $111.7 million a year earlier). Total revenues, net were $110.6 million for the quarter, including net product revenue of $71.5 million from Attruby in the U.S., license and services revenue of $37.4 million (which includes a $30.0 million regulatory milestone under the Eidos-Alexion License Agreement), and royalty revenue of $1.6 million from Beyonttra in the EU and Japan. Selling, general and administrative expenses rose to $129.2 million from $59.5 million, driven by commercial launch investments, while research and development expenses were $111.2 million, down from $114.7 million. The balance sheet shows cash, cash equivalents and marketable securities of $756.9 million as of June 30, 2025, against total liabilities of $2.86 billion and a total stockholders' deficit of $1.78 billion. Financing activity during the period included the issuance of $575.0 million of 1.75% convertible senior notes due 2031 and the repayment of the $450.0 million term loan under the Amended Financing Agreement. On June 27, 2025, the company sold a portion of its future royalties on Bayer's EU sales of acoramidis to royalty purchasers for $300.0 million in cash. The company states that its existing resources will fund operations for at least the next 12 months from the filing date, and that it expects to continue incurring operating and net losses for at least the next several years. During the quarter, the company's Attruby and Beyonttra commercial products were approved in the EU, Japan and UK, and the company implemented newly designed internal controls in connection with the commercial launch. Management concluded that disclosure controls and procedures were effective as of June 30, 2025.
BridgeBio Pharma 8-K Report, Financial Results (Aug 5, 2025)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) reported financial results for the second quarter ended June 30, 2025, in a press release furnished as Exhibit 99.1 to this Form 8-K under Item 2.02. Total revenues, net were $110.6 million for the quarter, comprised of $71.5 million of U.S. Attruby net product revenue, $1.6 million of royalty revenue, and $37.5 million of license and services revenue. The quarter's license and services revenue included a $30.0 million regulatory milestone from Alexion tied to pricing approval of BEYONTTRA in Japan. Operating costs and expenses rose to $244.8 million from $177.7 million, driven by a $69.6 million increase in selling, general and administrative expenses supporting the Attruby launch. The net loss attributable to common stockholders of BridgeBio was $181.9 million, or $0.95 per share, compared with $73.5 million, or $0.39 per share, a year earlier. The company ended the quarter with $756.9 million in cash, cash equivalents and marketable securities. The filing attributes the increase from $681.1 million at December 31, 2024 primarily to $563.0 million of net proceeds from the 2031 Notes issued in February 2025 and $297.0 million of net proceeds from a royalty interest sale to HealthCare Royalty and Blue Owl Capital in June 2025. These were partly offset by $279.9 million of net cash used in operating activities for the first half of 2025 and repayment of $459.0 million under the prior term loan. The company reported 3,751 unique Attruby prescriptions written by 1,074 prescribers as of August 1, 2025. The release outlines pipeline catalysts: topline results from the FORTIFY Phase 3 study of BBP-418 and the CALIBRATE Phase 3 study of encaleret, both expected in fall 2025, and topline results from the PROPEL 3 Phase 3 study of infigratinib in achondroplasia, expected in early 2026. Management described the next six months as transformative, with Phase 3 readouts across ADH1, LGMD2I/R9, and achondroplasia.
BridgeBio Pharma 8-K Report, Material Agreement (Jul 2, 2025)
BridgeBio Pharma, Inc. (the Company) disclosed in a Form 8-K that on June 27, 2025 (the Closing Date), it and its subsidiary Eidos Therapeutics, Inc. entered into a Royalty Interest Purchase and Sale Agreement with Acoramidis Royalty SPV, LP and LSI Financing Fund, LP as purchasers. Under the agreement, Eidos sold to the purchasers certain rights to receive royalty payments on net sales of acoramidis-containing products in the European Union and European Patent Organization member and extension states, arising under the Bayer License Agreement and an amended and restated license with BridgeBio International GmbH. The purchasers agreed to pay Eidos $300 million in cash, funded in full on the Closing Date. The purchased royalty rights are subject to an annual cap equal to 60% of royalty payments paid by Bayer on the first $500,000,000 of annual net sales of Licensed Products in the Licensed Territory under the Bayer License Agreement, and an initial hard cap equal to 145% of the Purchase Price. The Company and Eidos granted the purchaser representative a security interest in specific assets related to the purchased royalties. The filing also states that upon a change of control of the Company, a successor entity may either assume the obligations under the Purchase Agreement or pay the purchasers an Adjusted Amount, after which no further payments would be due. The complete agreement is to be filed as an exhibit to a subsequent periodic report.
BridgeBio Pharma 8-K Report, Rights Modification (Jun 23, 2025)
BridgeBio Pharma, Inc. reported in this Form 8-K that its stockholders approved several proposals at the June 20, 2025 Annual Meeting of Stockholders. The most significant governance change is an amendment to the Amended and Restated Certificate of Incorporation that limits the liability of certain officers as permitted under current Delaware law. The amendment was previously approved by the Board, became effective upon filing with the Delaware Secretary of State on June 23, 2025, and is filed as Exhibit 3.1. At the meeting, 173,876,974 of the 189,868,970 shares of common stock entitled to vote were present or represented by proxy. Stockholders elected five Class III directors, Neil Kumar, Ph.D., Charles Homcy, M.D., Douglas A. Dachille, Ronald J. Daniels and Andrew W. Lo, Ph.D., to serve until the 2028 Annual Meeting. They also approved, on a non-binding advisory basis, the compensation of the named executive officers, ratified Deloitte & Touche LLP as the independent registered public accounting firm for fiscal 2025, and approved an amendment and restatement of the 2021 Amended and Restated Stock Option and Incentive Plan that increases the shares reserved for issuance by 5,000,000. For investors, the filing's key items are the officer exculpation amendment, the expanded equity plan share reserve, and the advisory say-on-pay vote. The say-on-pay proposal received 117,646,141 votes for and 37,945,949 votes against, with 1,231,991 abstentions and 17,052,893 broker non-votes. The filing does not discuss business operations, financial results or other strategic developments.
BridgeBio Pharma Quarterly Report for Q1 Ended Mar 31, 2025
BridgeBio Pharma, Inc. reported a net loss of $169.6 million for the three months ended March 31, 2025, compared with a net loss of $36.2 million in the prior-year period. Total revenues, net were $116.6 million, down from $211.1 million, as license and services revenue fell to $79.9 million from $211.1 million. Net product revenue from Attruby in the U.S. was $36.7 million, and the filing notes that the $75.0 million regulatory milestone from Bayer, recognized in license and services revenue, was received in April 2025. Research and development expense decreased to $111.4 million from $141.0 million, while selling, general and administrative expense rose to $106.4 million from $65.8 million, mainly reflecting commercial activities for Attruby. During the quarter the company issued $575.0 million of 1.75% convertible senior notes due 2031 and used the proceeds to fully repay the $450.0 million principal term loan under its Amended Financing Agreement, along with $48.3 million to repurchase 1,405,411 shares of common stock. Cash and cash equivalents declined to $540.6 million from $681.1 million at December 31, 2024. Total stockholders' deficit was $1.64 billion, and total liabilities were $2.52 billion. Management states it expects its cash, cash equivalents and restricted cash to fund operations for at least the next 12 months, and it expects continued operating and net losses for at least the next several years. The filing also notes that Attruby received FDA approval on November 22, 2024, Beyonttra was approved by the European Commission on February 10, 2025 and in Japan on March 27, 2025, and that the company is pursuing three late-stage candidates: low-dose infigratinib for achondroplasia, encaleret for ADH1, and BBP-418 for LGMD2I/R9.
BridgeBio Pharma 8-K Report, Financial Results (Apr 29, 2025)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) reported financial results for the first quarter ended March 31, 2025, as furnished in Exhibit 99.1 to this Form 8-K. Total revenues, net were $116.6 million, compared with $211.1 million in the prior-year quarter, reflecting a $131.2 million decline in license and services revenue (to $79.9 million, including $75.0 million of regulatory milestone revenue tied to the European Commission's approval of BEYONTTRA) that was partly offset by $36.7 million of first full-quarter U.S. Attruby net product revenue. The company posted a net loss attributable to common stockholders of $167.4 million, or $0.88 per share, versus $35.2 million, or $0.20 per share, a year earlier. Operating costs and expenses rose to $221.0 million, driven by a $40.5 million increase in SG&A to support the Attruby commercial launch. Balance sheet and financing activity were significant in the quarter. Cash and cash equivalents fell to $540.6 million from $681.1 million at December 31, 2024, as net cash used in operating activities of $199.2 million and $459.0 million of term loan repayment, along with $48.3 million of common stock repurchases, outweighed $563.0 million of net proceeds from the issuance of 2031 Notes. The company also stated that its cash balance excludes $105 million in regulatory milestone payments anticipated in the second quarter for ex-U.S. approvals of BEYONTTRA. Thomas Trimarchi, Ph.D. was appointed President and Chief Financial Officer. On the pipeline, the filing highlights that the FORTIFY (BBP-418, LGMD2I/R9) and CALIBRATE (encaleret, ADH1) Phase 3 studies are fully enrolled with topline readouts expected in the second half of 2025, that PROPEL 3 (infigratinib, achondroplasia) topline results are expected in early 2026, and that a Phase 2 proof-of-principle study of encaleret in hypoparathyroidism showed 78% of N=9 participants achieving concomitant normal blood and urine calcium within 5 days.
BridgeBio Pharma 8-K Report, Executive Changes (Mar 17, 2025)
On March 17, 2025, BridgeBio Pharma, Inc. (Nasdaq: BBIO) reported under Item 5.02 that Brian C. Stephenson, its Chief Financial Officer, ended employment with the Company on that date. In connection with his transition, Dr. Stephenson will receive a lump sum payment equal to nine months of his current base salary and up to nine months of COBRA reimbursements, under his employment offer letter as amended on February 21, 2024. The Company also entered into a consulting agreement with Dr. Stephenson, under which he will provide consulting services from March 17, 2025 through March 17, 2026, unless earlier terminated. The full consulting agreement will be filed as an exhibit to the Company's Form 10-Q for the quarter ending March 31, 2025. Under Item 7.01, the Company announced that Thomas Trimarchi, Ph.D. has been appointed President and Chief Financial Officer. Dr. Trimarchi recently assumed the role of Principal Financial Officer and will continue to lead the Company's FP&A and accounting operations. According to the press release furnished as Exhibit 99.1, Dr. Stephenson is departing for personal reasons, not due to any disagreement with the Company on operations, policies or practices, and will continue to serve as a consultant. For investors, the filing signals a leadership change in the finance function, with continuity provided by the consulting arrangement and by Dr. Trimarchi's existing responsibility for FP&A and accounting. The filing does not describe any financial results or operational developments beyond these personnel changes.
BridgeBio Pharma 8-K Report, Material Agreement (Feb 28, 2025)
On February 28, 2025, BridgeBio Pharma, Inc. (BBIO) closed a private offering under Rule 144A of $575.0 million aggregate principal amount of 1.75% Convertible Senior Notes due March 1, 2031, including $75.0 million from the exercise in full of the initial purchasers' option. The notes are senior unsecured obligations, convertible into cash, common stock, or a combination at BridgeBio's election, with an initial conversion rate of 20.0773 shares per $1,000 principal (about $49.81 per share). Net proceeds were approximately $563.0 million. BridgeBio used a portion to repay all borrowings and terminate its Financing Agreement with lenders and Blue Owl Corporation, as administrative agent, and used approximately $48.3 million to repurchase shares of its common stock from certain note purchasers at $34.35 per share, the February 25, 2025 closing price. The filing states that the Financing Agreement, which contains various restrictive covenants, accounted for approximately $51.5 million of cash paid for interest in 2024, and that the refinancing is expected to reduce pro forma interest expense and provide greater operational flexibility. The company may not redeem the notes before March 6, 2028, and holders may require repurchase at 100% of principal plus accrued interest upon a fundamental change. The notes rank equally with the company's 2.50% Convertible Senior Notes due 2027 and 2.25% Convertible Senior Notes due 2029, and are effectively junior to its secured indebtedness and structurally junior to subsidiary liabilities. BridgeBio stated that the notes were issued in reliance on Section 4(a)(2) of the Securities Act and that a maximum of 16,739,400 shares of common stock may be issued upon conversion, based on an initial maximum conversion rate of 29.1120 shares per $1,000 principal amount.
BridgeBio Pharma Annual Report, Year Ended Dec 31, 2024
BridgeBio Pharma, Inc. reported a net loss of $543.3 million for 2024, compared with $653.3 million in 2023, as the company moved toward commercialization. Its first commercial product, Attruby (acoramidis), was approved by the FDA on November 22, 2024 for adults with ATTR-CM, and launched in the U.S. The European Commission approved acoramidis as Beyonttra on February 10, 2025, and Bayer plans a European launch in the first half of 2025. Revenue rose to $221.9 million in 2024 from $9.3 million in 2023, driven mainly by $207.7 million of upfront license and services revenue under the Bayer and Kyowa Kirin agreements. Net product revenue from Attruby was only $2.9 million, and the company states it has not yet generated substantial product revenue. The balance sheet carries significant leverage. Total consolidated indebtedness was $1.7 billion at December 31, 2024, including convertible notes and a senior secured term loan. The company also received $500.0 million under a Funding Agreement that carries a royalty of 5% of global Attruby net sales, which may rise to 10% in 2027, subject to a $950.0 million cap. Cash and cash equivalents were $681.1 million, and working capital was $566.3 million. The company states that cash and proceeds from Attruby revenue should fund operations for at least the next 12 months, and that the prior substantial doubt about going concern was resolved. Pipeline catalysts for 2025 include Phase 3 PROPEL 3 for low-dose infigratinib in achondroplasia, which completed enrollment in January 2025; Phase 3 FORTIFY interim analysis of BBP-418 for LGMD2I, with topline data expected in the second half of 2025; and a Phase 3 encaleret trial in ADH1, with topline results expected in the second half of 2025. The company's accumulated deficit reached $3.1 billion at year-end 2024.
BridgeBio Pharma 8-K Report, Financial Results (Feb 20, 2025)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) furnished a Form 8-K on February 20, 2025 reporting its fourth quarter and full year 2024 financial results and a commercial update on Attruby (acoramidis). As of February 17, 2025, 1,028 unique patient prescriptions for Attruby had been written by 516 unique prescribers since FDA approval on November 22, 2024. Full year 2024 revenue was $221.9 million, up from $9.3 million in 2023, driven mainly by $207.7 million recognized from upfront payments and services revenue under the Bayer and Kyowa Kirin agreements, plus $2.9 million in net product revenue from Attruby. Net loss attributable to common stockholders of BridgeBio was $535.8 million for the year, or $2.88 per share, compared with $643.2 million, or $3.95 per share, in 2023. Cash, cash equivalents and short-term restricted cash totaled $681.2 million at December 31, 2024, and net cash used in operating activities was $520.7 million for the year. The company also highlighted a European approval of acoramidis as BEYONTTRA on February 10, 2025, which triggered a $75 million milestone payment, and expects $105 million in regulatory milestones in the first half of 2025 from acoramidis approvals in Europe and Japan. Three Phase 3 studies (FORTIFY, CALIBRATE and PROPEL 3) are fully enrolled, with last participant last visit expected in 2025 before year-end. Cash-flow financing during 2024 included a $488.8 million net Funding Agreement, $434.0 million net term loan proceeds, and $314.7 million from equity offerings. The filing is furnished under Item 2.02 and is not deemed filed for Section 18 purposes. Operating costs rose to $814.9 million in 2024 from $616.7 million, largely from a $138.3 million increase in SG&A tied to the Attruby launch, and the year included $25.0 million of nonrecurring deal-related costs.
BridgeBio Pharma 8-K Report, Financial Results (Jan 13, 2025)
BridgeBio Pharma, Inc. furnished a press release and a J.P. Morgan Healthcare Conference presentation with its 8-K filed January 13, 2025. The Company states that it received $500 million upon U.S. Food and Drug Administration approval of acoramidis, from its royalty facility. It also reports $406 million in cash as of the last quarter. The Company describes the financial information in Item 2.02 as unaudited and preliminary, notes that the audit of its financial statements for the year ended December 31, 2024 is ongoing, and states that the audit could change this information. On the commercial side, the Company reports 430 Attruby (acoramidis) prescriptions written by 248 unique healthcare providers since FDA approval on November 22, 2024. Attruby is indicated to reduce cardiovascular death and cardiovascular-related hospitalization in adults with ATTR-CM. The Company anticipates $105 million in regulatory milestones in the first half of 2025 from European Union and Japan approvals of acoramidis. The Company reports that it has fully enrolled three Phase 3 trials: FORTIFY (BBP-418 for LGMD2I/R9, 112 patients), CALIBRATE (encaleret for ADH1, 70 patients), and PROPEL 3 (infigratinib for achondroplasia, 114 participants). It expects last patient or participant last visit and topline readouts for FORTIFY and CALIBRATE, and last participant last visit for PROPEL 3, in the second half of 2025.
BridgeBio Pharma 8-K Report, Corporate Update (Nov 25, 2024)
On November 25, 2024, BridgeBio Pharma, Inc. (BBIO) reported in a Form 8-K that the U.S. Food and Drug Administration approved Attruby (acoramidis), an oral near-complete (≥90%) stabilizer of transthyretin (TTR), to reduce cardiovascular death and cardiovascular-related hospitalization in adults with ATTR-CM. The approval is based on the Phase 3 ATTRibute-CM study, which enrolled 632 participants randomized 2:1 to Attruby or placebo for 30 months. The trial met its primary composite endpoint with a Win Ratio of 1.8 (p<0.0001), and the filing reports a 42% reduction in composite all-cause mortality and recurrent cardiovascular-related hospitalization relative to placebo at Month 30, and a 50% reduction in the cumulative frequency of cardiovascular-related hospitalization events. The company disclosed commercial terms in the filing. The recommended dose is 712 mg (two 356 mg tablets) taken twice daily, with a list price of $18,759.12 for a 28-day supply. BridgeBio states that the approval triggers a $500 million payment under its royalty funding agreement. The filing also notes that the company has only recently begun establishing its sales force and commercialization capabilities, and that reimbursement, pricing and competition are key risks. Reported adverse reactions were mostly mild: diarrhea (11.6% vs 7.6% for placebo) and upper abdominal pain (5.5% vs 1.4%), with discontinuation rates due to adverse events of 9.3% for Attruby and 8.5% for placebo. Outside the U.S., BridgeBio submitted a Marketing Authorization Application to the European Medicines Agency, with a decision expected in 2025, and has granted Bayer exclusive rights to commercialize acoramidis for ATTR-CM in Europe. The company also plans to pursue approvals in Japan and Brazil. BridgeBio will provide Attruby free for life to U.S. clinical trial participants.
BridgeBio Pharma Quarterly Report for Q3 Ended Sep 30, 2024
BridgeBio Pharma, Inc. (BridgeBio) reported a net loss of $164.3 million for the three months ended September 30, 2024 and $276.0 million for the nine months, compared with $482.9 million for the nine months ended September 30, 2023. Revenue for the nine months rose to $216.0 million from $7.6 million, driven mainly by $205.3 million of upfront license fee and services revenue under the Bayer Agreement and the KKC Agreement, while three-month revenue was $2.7 million. Cash and cash equivalents were $266.3 million and restricted cash was $139.4 million at September 30, 2024, and total stockholders' deficit was $1.22 billion. Net cash used in operating activities was $325.4 million for the nine months. The filing states that substantial doubt exists about the company's ability to continue as a going concern for one year from November 12, 2024. Management plans to alleviate this doubt by receiving a $500.0 million milestone payment under the Funding Agreement upon FDA approval of acoramidis, together with product revenues if approved. The company anticipates FDA approval in late November 2024 but cannot guarantee the approval, the timing of the payment, or the resulting product revenues, and may need to raise additional capital. During 2024 the company restructured its portfolio: it deconsolidated GondolaBio and BBOT (TheRas, Inc.), recognizing gains of $52.0 million and $126.3 million respectively, ceased development of BBP-631 for congenital adrenal hyperplasia, and terminated the Navire-BMS License Agreement. Its outstanding debt was $1.7 billion, including $747.5 million of 2029 Notes, $550.0 million of 2027 Notes, and a $450.0 million term loan under the Amended Financing Agreement, with a $70.0 million minimum qualified cash balance that was $78.0 million as of September 30, 2024.
BridgeBio Pharma 8-K Report, Financial Results (Nov 12, 2024)
BridgeBio Pharma, Inc. reported its third-quarter 2024 financial results and business update on November 12, 2024. Revenue was $2.7 million for the quarter and $216.0 million for the nine months ended September 30, 2024, versus $4.1 million and $7.6 million in the prior-year periods. The nine-month increase was primarily due to recognition of non-refundable upfront payments and service revenue under the Bayer and Kyowa Kirin exclusive license and collaboration agreements. Net loss attributable to common stockholders was $162.0 million ($0.86 per share) for the quarter and $270.7 million ($1.46 per share) for the nine months. Operating costs and expenses rose, driven by selling, general and administrative expenses that the company attributes to commercialization readiness, and by higher research and development expenses for the nine months. Third-quarter operating costs and expenses were $194.5 million. The company ended the quarter with $405.7 million of cash, cash equivalents and short-term restricted cash. Financing activity during the nine months included $434.0 million in net proceeds from a term loan under a credit facility with Blue Owl and $314.7 million in net proceeds from equity financings, offset by $473.4 million used to refinance its previous senior secured term loan, including prepayment fees and exit-related costs. Net cash used in operating activities was $325.4 million for the nine months. The company anticipates receiving a $500 million milestone payment upon FDA approval of acoramidis and $105 million in aggregate regulatory milestone payments upon approval in European and Japanese territories. The key near-term catalyst is the November 29, 2024 PDUFA action date for acoramidis in ATTR-CM, for which a new drug application has been accepted. The company also expects three Phase 3 readouts in 2025, including the interim analysis of FORTIFY for BBP-418 in LGMD2I/R9, and it plans to share 42-month outcomes data from the acoramidis open-label extension at the American Heart Association Scientific Sessions on November 18.
BridgeBio Pharma 8-K Report, Corporate Update (Sep 11, 2024)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) reported topline results on September 10, 2024 from the Phase 1/2 open-label ADventure study of BBP-631, its investigational AAV5 gene therapy for congenital adrenal hyperplasia (CAH). The company stated that increased endogenous cortisol production was achieved in all patients at higher doses, with maximum changes from baseline post-ACTH stimulation of 4.7 μg/dL and 6.6 μg/dL at the two highest dose levels, and that BBP-631 was well tolerated with no treatment-related serious adverse events reported. Despite these results, BridgeBio said the data do not warrant additional capital investment at this time. The company will no longer pursue development of BBP-631 for CAH, will reduce the gene therapy budget by more than $50 million, and is actively seeking partnership opportunities to support future development of BBP-631 or next-generation gene therapies for CAH. Management described the data as "not yet transformational" while noting the study showed for the first time that people with CAH can make their own cortisol and that gene therapy can be safely administered in this population. The company also said it will reserve gene therapy for priority targets it cannot treat any other way, and that it is eager to work with the FDA and the Canavan community toward bringing its therapy to families with Canavan disease.
BridgeBio Pharma 8-K Report, Material Agreement (Aug 21, 2024)
BridgeBio Pharma, Inc. reported on Form 8-K that on August 16, 2024, it entered into a Transaction Agreement, approved by a special committee of independent and disinterested directors, to form and fund GondolaBio, LLC, a joint venture for researching, developing, manufacturing and commercializing pharmaceutical products, including programs the Company contributed. The Transaction closed on the date the agreement was signed. The Company contributed certain early-stage clinical and pre-clinical programs in Erythropoietic Protoporphyria, Alpha-1 Antitrypsin Deficiency, and Tuberous Sclerosis Complex. Certain third-party investors have committed $300 million of tranched financing to GondolaBio. The investor syndicate includes Viking Global Investors LP, Patient Square Capital, Sequoia Capital, Frazier Life Sciences, Cormorant Asset Management, Aisling Capital, and an entity owned by Neil Kumar, the Company's Chief Executive Officer. The Company's initial interest in GondolaBio will be approximately 45%, subject to reduction as additional capital tranches are funded. On the same date, BridgeBio Pharma LLC, a wholly owned subsidiary, became a party to the Amended and Restated Limited Liability Company Agreement of GondolaBio, which sets out the members' economic and governance rights. Goldman Sachs & Co. LLC advised the special committee as financial advisor, and Skadden, Arps, Slate, Meagher & Flom LLP advised the Company. The Transaction Agreement and LLC Agreement are filed as Exhibits 10.1 and 10.2.
BridgeBio Pharma Quarterly Report for Q2 Ended Jun 30, 2024
BridgeBio Pharma, Inc. ("BridgeBio") reported a net loss of $111.7 million for the six months ended June 30, 2024, compared with $303.4 million in the same period of 2023, and a net loss of $75.5 million for the three months ended June 30, 2024. Six-month revenue was $213.3 million, up from $3.5 million a year earlier, driven mainly by $202.9 million recognized from the upfront license fees and services revenue under the Bayer Agreement and the KKC Agreement. Research and development expense rose to $255.7 million for the six months and selling, general and administrative expense rose to $125.3 million, reflecting commercialization readiness efforts. The three-month period also included a $126.3 million non-cash gain from deconsolidating TheRas, Inc. (BridgeBio Oncology Therapeutics), following its $200.0 million private equity financing in which BridgeBio's ownership fell to approximately 37.9%. At June 30, 2024, cash, cash equivalents and marketable securities totaled $447.8 million, with restricted cash of $139.4 million, largely escrowed under the Financing Agreement from asset sale proceeds. Total debt principal included $747.5 million of 2029 Notes, $550.0 million of 2027 Notes and a $450.0 million term loan under the Amended Financing Agreement, which was used to repay the prior term loan in January 2024. Stockholders' deficit improved to $1.08 billion from $1.34 billion at December 31, 2023, following public offerings that raised $314.8 million in net proceeds during the first half of 2024. The company stated that its cash and equivalents should fund operations for at least the next 12 months. A pending Funding Agreement would provide $500.0 million upon the first FDA approval of acoramidis, which had been submitted to the FDA on December 5, 2023.
BridgeBio Pharma 8-K Report, Financial Results (Aug 1, 2024)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) reported its financial results for the second quarter ended June 30, 2024, and an operational update in a press release furnished as Exhibit 99.1 to this Form 8-K. Revenue was $2.2 million for the three months ended June 30, 2024 and $213.3 million for the six months, compared with $1.6 million and $3.5 million in the prior-year periods. The six-month increase was primarily driven by $202.9 million of non-refundable upfront payments and service revenue under the Bayer and Kyowa Kirin exclusive license and collaboration agreements. Net loss attributable to common stockholders of BridgeBio was $73.5 million for the quarter ($0.39 per share), compared with $157.9 million ($0.98 per share) a year earlier, and $108.7 million for the six months ($0.59 per share). The quarterly result benefited from a $126.3 million gain on deconsolidation of a subsidiary. Cash, cash equivalents, marketable securities and short-term restricted cash totaled $587.2 million at June 30, 2024, up from $392.6 million at December 31, 2023, reflecting $434.0 million of net term loan proceeds from Blue Owl and $314.8 million of net equity financing proceeds, partly offset by $473.4 million used to refinance the prior senior secured term loan and $144.8 million of operating cash outflow for the six months. On the pipeline, the company highlighted that the NDA for acoramidis for ATTR-CM has a PDUFA date of November 29, 2024, and that new analyses presented at the 2024 ISA and ESC-HF Congress included a statistically significant reduction in all-cause mortality (p=0.04) in the intention-to-treat population of ATTRibute-CM. Low-dose infigratinib in Cohort 5 of PROPEL 2 showed a statistically significant increase in annualized height velocity of +2.50 cm/yr at Month 18 (p=0.0015). BridgeBio surpassed the interim analysis enrollment target for the Phase 3 FORTIFY study of BBP-418 in LGMD2I/R9, with interim top-line results expected in 2025. The company expects to complete enrollment in its three Phase 3 programs by the end of 2024 and reports three readouts expected in 2025.
BridgeBio Pharma 8-K Report, Executive Changes (Jul 23, 2024)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) filed a Current Report on Form 8-K dated July 23, 2024, announcing a leadership change in its executive team. Thomas Trimarchi was appointed President and Chief Operating Officer, effective July 23, 2024, succeeding Neil Kumar, Ph.D., who stepped down as President but continues as a director and Chief Executive Officer. Dr. Trimarchi, age 39, had served as the Company's Chief Product Officer from April 2018 to July 2024 and has been a board member of the affiliate ML Bio Solutions, Inc. since November 2021. According to the accompanying press release (Exhibit 99.1), the newly created COO role is responsible for driving operational excellence, strategic planning, and overall business success. Dr. Trimarchi will lead cross-functional activities to develop a centralized operation across the late-stage pipeline, prioritizing efficiency, rigor, and scale. He will continue to report directly to Dr. Kumar. The filing states there are no arrangements or understandings between Mr. Trimarchi and any other persons related to his appointment, and no family relationships with the Company's directors or executive officers. The press release is furnished under Item 7.01 and is not deemed filed for purposes of Section 18 of the Exchange Act.
BridgeBio Pharma 8-K Report, Shareholder Vote Results (Jun 24, 2024)
BridgeBio Pharma, Inc. reported the results of its Annual Meeting of Stockholders, held June 21, 2024, in this Current Report. Of the 187,129,260 shares of common stock entitled to vote, 160,899,203 were present or represented by valid proxy. Stockholders elected all five Class II director nominees (Eric Aguiar, M.D., Jennifer E. Cook, Andrea J. Ellis, Fred Hassan and Ali J. Satvat) to terms ending at the 2027 Annual Meeting. Ali J. Satvat received the lowest support, with 106,237,448 votes for and 37,395,306 withheld, compared with 137,076,192 to 139,229,888 votes for the other four nominees. Stockholders also approved, on a non-binding advisory basis, the compensation of the named executive officers, with 134,309,832 votes for, 9,254,636 against and 68,286 abstentions. They ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, with 160,661,642 votes for, 196,629 against and 40,932 abstentions. Stockholders approved an amendment and restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan, which, among other things, increases the number of shares reserved for issuance by 6,500,000 shares. The vote was 118,318,376 for, 25,003,526 against and 310,852 abstentions, with 17,266,449 broker non-votes. The amended plan is filed as Exhibit 10.1.
BridgeBio Pharma 8-K Report, Corporate Update (Jun 6, 2024)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) reported in a June 4, 2024 press release, furnished as Exhibit 99.1 to this Current Report under Item 8.01, sustained positive results from Cohort 5 (0.25 mg/kg/day) of PROPEL 2, a Phase 2 trial of oral infigratinib in children with achondroplasia. Treatment produced a statistically significant and sustained mean increase in annualized height velocity of +2.51 cm/yr from baseline at Month 12 and +2.50 cm/yr at Month 18 (p=0.0015). At Month 18, body proportionality improved, with the mean upper to lower body segment ratio falling to 1.88 from 2.02 at baseline (p=0.001). The company stated that infigratinib remained well-tolerated, with no adverse events assessed as treatment-related in any Cohort 5 participant. The company said PROPEL 3, its global Phase 3 registrational study of infigratinib in achondroplasia, continues to enroll on schedule, with completion of enrollment anticipated by the end of 2024. BridgeBio also announced it is accelerating development in hypochondroplasia, citing positive interactions with the U.S. FDA and EMA. The first participant was consented in May 2024 into ACCEL, the observational lead-in study. The planned interventional ACCEL 2/3 program will include an open-label Phase 2 portion in children aged 5 to 11 followed by a pivotal, one-year, 2:1 randomized, double-blinded, placebo-controlled Phase 3 study. The filing is a short notice of a press release. It does not disclose financial results, financing, or guidance. Investors should note that the data are from a small dose-escalation cohort, and the press release itself lists forward-looking risks, including that initial and ongoing trial data may not be indicative of final data.
BridgeBio Pharma 8-K Report, Financial Results (May 2, 2024)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) reported first quarter 2024 financial results and business updates on May 2, 2024, as furnished in Exhibit 99.1 to this Form 8-K. Revenue for the quarter was $211.1 million, compared with $1.8 million in the prior-year period, primarily from recognition of non-refundable upfront payments under the Bayer and Kyowa Kirin exclusive license agreements. Operating costs and expenses rose to $210.8 million from $128.0 million, including $22.5 million of nonrecurring deal-related costs. The company reported a net loss of $36.2 million, or $0.20 per share, compared with a net loss of $142.7 million in the prior-year quarter. Cash, cash equivalents, marketable securities and short-term restricted cash totaled $519.8 million at March 31, 2024, up from $392.6 million at December 31, 2023. The company highlighted acoramidis for ATTR-CM, with an NDA PDUFA date of November 29, 2024 set by the FDA and an MAA accepted by the EMA with approval expected in 2025. It also licensed European commercial rights to acoramidis to Bayer, in exchange for tiered royalties beginning in the low-thirties percent and up to $310 million in upfront and near-term milestone payments. The company also launched BridgeBio Oncology Therapeutics (BBOT) with a $200 million private financing. Management stated that it believes it has a strong financial position to launch acoramidis in the U.S. at the end of 2024 and deliver three Phase 3 readouts in 2025. The balance sheet showed total stockholders' deficit of $1.05 billion at March 31, 2024, reflecting $737.4 million in 2029 Notes, $543.8 million in 2027 Notes and $434.7 million in term loan, net. Net cash used in operating activities was $219.5 million for the quarter. The company also noted that Bristol-Myers Squibb (BMS) provided notice in March 2024 to terminate the Navire-BMS License Agreement, with termination effective in June 2024.
BridgeBio Pharma Quarterly Report for Q1 Ended Mar 31, 2024
BridgeBio Pharma, Inc. (BridgeBio) reported a net loss of $36.2 million for the three months ended March 31, 2024, a substantial improvement from a net loss of $142.7 million in the prior-year period. Revenue rose to $211.1 million from $1.8 million, driven mainly by $201.2 million of upfront license fee and services revenue from the Bayer Agreement and the KKC Agreement, plus $9.9 million from the terminated Navire-BMS License Agreement. Research and development expenses increased to $141.0 million from $92.9 million, and selling, general and administrative expenses increased to $65.8 million from $31.1 million, including $14.0 million of nonrecurring deal-related expenses. The balance sheet strengthened over the quarter. Cash, cash equivalents and marketable securities were $519.7 million at March 31, 2024, compared with $375.9 million at December 31, 2023, supported by a $450.0 million Initial Term Loan under a Financing Agreement with Blue Owl Capital Corporation and about $315.3 million of net proceeds from public offerings. The company used the proceeds to fully repay its prior term loan, which carried a $26.6 million loss on extinguishment of debt. Total stockholders' deficit narrowed to $(1,037.4) million from $(1,343.0) million, and the accumulated deficit was $2.6 billion. The company stated it expects its existing resources to fund operations for at least the next 12 months. Key forward-looking items include a $500.0 million funding agreement payable upon first FDA approval of acoramidis, in exchange for a 5% royalty on global net sales of acoramidis, and a requirement to deposit 75% of proceeds from certain asset sales into an escrow account under the Financing Agreement. The company also recorded new restructuring plans with an estimated remaining $12.0 million to $16.0 million in charges. A subsequent event on April 30, 2024 was a $200.0 million private financing of BridgeBio Oncology Therapeutics, which the company is still evaluating.
BridgeBio Pharma 8-K Report, Material Agreement (Mar 6, 2024)
On March 5, 2024, BridgeBio Pharma, Inc. entered into an Underwriting Agreement with J.P. Morgan Securities LLC, Cantor Fitzgerald & Co. and Mizuho Securities USA LLC, as representatives of the underwriters, for an underwritten public offering of 8,620,690 shares of common stock at $29.00 per share. The Company estimates net proceeds of approximately $250.0 million, excluding any exercise of the underwriters' 30-day option to purchase up to an additional 1,293,103 shares. The offering is expected to close on or about March 8, 2024, subject to customary closing conditions, and is being made under an effective Form S-3ASR shelf registration statement. The Company said it expects to use the net proceeds to fund the commercial launch of acoramidis, if approved, and the clinical and pre-clinical development of its current and future product candidates, research activities, and working capital and general corporate purposes. It may also use a portion of the proceeds to invest in or acquire complementary businesses or technologies, though it stated it has no current plans, commitments or agreements for any such material investments or acquisitions. The Company believes its existing cash and cash equivalents, together with the offering proceeds, will be sufficient to fund operations into the second half of 2026. The Company and its directors and executive officers agreed not to sell or transfer Common Stock for 60 days after the Prospectus date, subject to certain exceptions and the written consent of J.P. Morgan Securities LLC. The filing also includes the Underwriting Agreement and a legal opinion from Goodwin Procter LLP as exhibits, and two press releases: one announcing the launch of the offering on March 4, 2024 and one announcing its pricing on March 5, 2024.
BridgeBio Pharma 8-K Report, Material Agreement (Mar 4, 2024)
BridgeBio Pharma, Inc. (the "Company") reported in this Form 8-K filed March 4, 2024 that certain of its subsidiaries, including Eidos Therapeutics, Inc. ("Eidos"), BridgeBio International GmbH and BridgeBio Europe B.V., entered into an exclusive license agreement on March 1, 2024 with Bayer Consumer Care AG, a wholly-owned subsidiary of Bayer AG ("Bayer"). The agreement covers developing and commercializing acoramidis as a treatment for transthyretin amyloidosis in the European Union and all member states of the European Patent Organization (the "Licensed Territory"). Under the agreement, Eidos grants Bayer an exclusive license to certain intellectual property rights for acoramidis (AG10) in the Licensed Territory, effective upon receipt of certain antitrust clearances. In consideration, Eidos is entitled to receive up to $310 million in upfront, regulatory and sales milestone payments through 2026, plus additional payments tied to certain sales milestones. Eidos is also entitled to tiered royalties starting in the low-thirties percent on Bayer's net sales of acoramidis in the Licensed Territory, subject to reduction in certain circumstances. The agreement runs until the end of the royalty term for a licensed product, unless terminated earlier. Either party may terminate for material breach or insolvency of the other, or if merger control proceedings start and clearances are not obtained. Bayer may terminate for convenience on at least 270 days' prior written notice, and Eidos may terminate if Bayer ceases exploitation of acoramidis under certain circumstances or challenges Eidos' patent rights. The full agreement will be filed as an exhibit to the Company's Form 10-Q for the quarter ending March 31, 2024.